Beyond PEGylation: Next-Generation Nanomedicine for Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 9
Special Issue Editor
Interests: genetically engineered materials; nanotechnology; drug and gene delivery; anti-cancer therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The landscape of cancer nanomedicine is rapidly evolving beyond traditional PEGylation and liposomal formulations. Novel strategies—including brush polymers, zwitterionic coatings, biomimetic carriers, and stimuli-responsive systems—are redefining how current and emerging drugs can be reformulated to enhance efficacy, safety, and patient compliance. This Special Issue will highlight advances in polymer–drug conjugates, lipid nanoparticle innovations, tumor-targeting mechanisms, and translational approaches, bridging preclinical discovery with clinical applications. Contributions should cover experimental, computational, and regulatory perspectives, with emphasis on scalable technologies that address immunogenicity, drug resistance, and delivery barriers. Together, the contributions showcased in this Special Issue will illuminate the upcoming developments in precision cancer nanomedicine.
Dr. Soumen Saha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- tumor-targeting mechanisms
- cancers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
